[go: up one dir, main page]

WO2001037865A1 - Compositions et methodes pour le traitement des troubles allergiques - Google Patents

Compositions et methodes pour le traitement des troubles allergiques Download PDF

Info

Publication number
WO2001037865A1
WO2001037865A1 PCT/AU2000/001414 AU0001414W WO0137865A1 WO 2001037865 A1 WO2001037865 A1 WO 2001037865A1 AU 0001414 W AU0001414 W AU 0001414W WO 0137865 A1 WO0137865 A1 WO 0137865A1
Authority
WO
WIPO (PCT)
Prior art keywords
bacteria
probiotic bacteria
administration
antigen
administered
Prior art date
Application number
PCT/AU2000/001414
Other languages
English (en)
Inventor
Robert Llewellyn Clancy
Gerald Pang
Original Assignee
Probiall Pty Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probiall Pty Limited filed Critical Probiall Pty Limited
Priority to BR0015698-1A priority Critical patent/BR0015698A/pt
Priority to EP00975685A priority patent/EP1229930A4/fr
Priority to HK03100999.8A priority patent/HK1049115A1/zh
Priority to CA002391499A priority patent/CA2391499A1/fr
Priority to AU13734/01A priority patent/AU782689B2/en
Priority to JP2001539479A priority patent/JP2003514869A/ja
Priority to KR1020027006409A priority patent/KR20020084066A/ko
Publication of WO2001037865A1 publication Critical patent/WO2001037865A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/113—Acidophilus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/125—Casei
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/335—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Lactobacillus (G)

Definitions

  • the invention relates to the field of allergic disease prevention and/or treatment, and in particular to probiotic bacteria which have the capacity to prevent and/or treat allergic disease.
  • BACKGROUND ART Allergy is a clinical syndrome affecting about one third of the population, manifest as rhinitis, asthma, eczema or food hypersensitivity.
  • target tissue changes play a role in determining the pattern of disease
  • the central abnormality (known as atopy) is the genetically influenced propensity to develop an IgE antibody response following antigen exposure.
  • atopy the central abnormality
  • the characteristics of the gut bacterial flora may drive IgE-promoting immunological mechanisms possibly by affecting the cytokine balance produced by CD4+ T lymphocytes.
  • the present invention provides a method of lowering IgE levels by administration of a therapeutically effective amount of live probiotic bacteria, or a live probiotic bacteria-containing composition, to a subject in need thereof.
  • a method of prophylactic or therapeutic treatment of allergy by administration to a subject requiring such treatment a therapeutically effective amount of live probiotic bacteria, or a live probiotic bacteria- containing composition preferably, the probiotic bacteria is, or the probiotic bacteria-containing composition includes. Lactobacillus.. Most preferably, the Lactobacillus is Lactobacill s acidophil s and/or Lactobacillus casei.
  • IgE is lowered from elevated levels induced by an allergen or as a consequence of an allergic disorder.
  • the probiotic bacteria, or a probiotic bacteria-containing composition is administered at the time of exposure to an allergen or shortly thereafter.
  • the term "exposure" with reference to an antigen or allergen includes natural exposure such as for example day-to-day contact with or ingestion of food products and the like, or seasonal exposure or re-exposure to allergens such as pollen or other air-borne allergens or by contact with skin and other body surfaces which may involve contact with synthetic materials or natural substances.
  • allergens such as pollen or other air-borne allergens or by contact with skin and other body surfaces which may involve contact with synthetic materials or natural substances.
  • the probiotic bacteria or compositions containing such bacteria are preferably administered at the time of exposure to the antigen/allergen or shortly thereafter.
  • the treatment is preferably commenced at the beginning of the season or shortly thereafter.
  • the term “exposure” includes natural exposure such as for example day-to-day contact with or ingestion of food products and the like, or seasonal exposure or re-exposure to allergens such as pollen or other air-borne allergens or by contact with skin and other body surfaces which may involve contact with synthetic materials or natural substances.
  • antigen/allergen when used with reference to antigen/allergen also includes artificial exposure or administration such as for example the injection of antigen/allergen in desensitisation procedures or under-tongue administration of antigen/allergen.
  • the antigen/allergen is preferably co-administered (co-presented) with the probiotic bacteria or a composition containing them.
  • probiotic bacteria may also be administered shortly after administration of the antigen/allergen.
  • the subject in need thereof is selected from the group consisting of high risk infants; those subjected to high risk occupational exposure to allergens; those exposed to high risk allergens; those having recognised allergy to specific allergens; and those prone to anaphylaxis.
  • the high risk infants are children of parents who both have allergic disease.
  • those subject to high risk occupation exposure to allergens are selected from the group consisting of aluminium smelter workers, woodworkers, chemical factory workers, and those working with latex-containing materials, especially gloves.
  • those exposed to high risk allergens are exposed to bee venom.
  • exposure to high risk allergens is parenteral exposure.
  • the specific allergens are present in the pre-pollen season, foods or latex-containing materials.
  • the trigger for the allergic response is insect envenomation, and food and drug sensitivities.
  • the probiotic bacteria or probiotic bacteria-containing composition is in tablet or capsule form.
  • the probiotic bacteria may be present in a food source such as a yoghurt or other dairy product.
  • the amount of probiotic bacteria administered to a human subject is at least 10 10 live bacteria. More preferably the amount administered is from about 10 10 to about 10 n live bacteria.
  • the required dosage amount will vary according to the severity of the allergic condition, the nature of the allergic condition, age of the subject and other standard clinical parameters. These parameters as well as the required dosage can be easily assessed by those skilled in the art. In human subjects it is preferred that the probiotic bacteria or a composition containing them be administered daily.
  • the present invention provides the use of live probiotic bacteria for the manufacture of a medicament for lowering IgE levels.
  • the present invention provides use of live probiotic bacteria for the manufacture of a medicament for treating allergy.
  • the present invention provides a method of identifying a bacterial species capable of lowering IgE levels in a mammal including: a) administration of the bacterial species to a mammal; b) administration of an allergen (antigen) to the mammal; and c) determination of the IgE antibody level in the mammal after treatment with the bacterial species and comparison with a control mammalian which a bacterial species
  • steps (a) and (b) were not administered, wherein steps (a) and (b) can be performed consecutively in any order or simultaneously.
  • the bacterial species is a Lactobacillus species and most preferably it is Lactobacillus acidophilus or Lactobacillus casei.
  • the animal model for identifying useful probiotic bacteria preferably makes use of the mouse.
  • other animal models may be developed on the same principle as disclosed herein.
  • the bacterial species is preferably administered orally however it may also be administered intraperitoneally and other means. Most preferably, the
  • 15 bacterial species is administered in an amount of 10 8 to 10" bacteria, and more preferably, in an amount of 0.6 to 1.0 x 10'° bacteria.
  • 1 to 20 oral doses are administered prior to administration of the antigen and most preferably 4 to 8 oral doses are administered prior to administration of the antigen.
  • administration of the oral doses is at 1 to 5 day intervals and, most preferably, at 2 day intervals.
  • 0 administration is over a 1 to 3 week period and, most preferably, over a 1 to 2 week period.
  • the antigen is administered at 5 a dose of 4 to 10 ⁇ g, and most preferably, at a dose of 8 ⁇ g.
  • the antigen is administered intraperitoneally.
  • the bacterial species is administered at the same time or 1 day after administration of the antigen/allergen.
  • the antigen/allergen can be administered after the bacterial species and in such circumstances the antigen/allergen is administered preferably 1 day after the 0 administration of 4 to 8 oral doses of bacteria.
  • administration of the bacteria species is continued after administration of the antigen. Most preferably, approximately 8 oral doses of bacteria are administered.
  • the bacteria are administered at 2 day intervals.
  • the IgE antibody is obtained from serum.
  • the serum is collected approximately 14 days after administration of the antigen.
  • the IgE antibody level is determined using an ELISA assay.
  • the skilled addressee will recognise that other IgE antibody assays may also be used.
  • the allergic disease is selected from the group consisting of asthma, eczema, hayfever and food allergy.
  • the present invention provides a bacterial species identified by the method of the fourth aspect.
  • the present invention provides a composition including a bacterial species according to the fourth aspect.
  • composition is in the form of a capsule or tablet or similar formulation however it may also be in the form of a food product.
  • a pharmaceutical composition including an effective amount of live bacterial species according to the fourth aspect, together with a pharmaceutically acceptable carrier, adjuvant, solvent or excipient.
  • the bacterial species is L. acidophilus.
  • a method of assessing efficacy of treatment with live probiotic bacteria or with a composition having live probiotic bacteria including the steps of: a measuring the level of salivary immunoglobulin subclass in a sample obtained before commencement of treatment, b measuring the level of salivary immunoglobulin subclass in a sample obtained after commencement of treatment c comparing the levels of salivary immunoglobulin subclass in a) and b), wherein the change in immunoglobulin subclass level is indicative of effective treatment.
  • the immunoglobulin subclass is IgGl or IgG2 and it will be understood that equivalent subclasses in various species can also be advantageously used.
  • a method of assessing efficacy of treatment with live probiotic bacteria or with a composition having live probiotic bacteria including the steps of: a measuring the level of LL-4 or IFN- ⁇ in a sample obtained before commencement of treatment, b measuring the level of IL-4 or IFN- ⁇ in a sample obtained after commencement of treatment c comparing the levels of IL-4 or IFN- ⁇ in a) and b), wherein the change in IL-4 or
  • IFN- ⁇ level is indicative of effective treatment. It will be clear however that any know cytokine marker for the Thl or the Th2 response will be suitable in place of IFN- ⁇ or IL-4.
  • Figure 1 Suppression of IgE antibody response in mice fed probiotic bacteria.
  • Figure 5 Suppression of IgE response to OVA, and cytokine and IgG antibody subclass response, by L acidophilus
  • a mouse animal model was developed which enabled identification of probiotic bacteria capable of downregulating the IgE response to an antigen/allergen.
  • the animal used is a mouse (for example C57BL/6).
  • the animals are fed the candidate bacterial species (alive, dose 10 8 -10" , frequency every 1 -5 days, for 1 -3 weeks).
  • the animals are fed the bacteria at the same time as the antigen was being introduced or shortly thereafter, for example the following day.
  • Mice were immunised intraperitoneally with antigen (for example ovalbumin) at an appropriate dose (eg 4-1 O ⁇ g, preferably 8 ⁇ g), with specific and total IgE measured in serum (eg. at 14 days after immunisation).
  • antigen for example ovalbumin
  • specific and total IgE measured in serum eg. at 14 days after immunisation.
  • feeding with test bacteria continues throughout the experiment (see examples).
  • comparisons are made with killed organisms and dose-response is estimated.
  • timing of administration of probiotic bacteria in relation to antigen/allergen challenge is examined. The examples demonstrate: (i) that frequent dosage with live probiotic bacteria at an appropriate does can reduce the IgE response to antigen/allergen.
  • oral administration of the bacterial species affects the systemic IgE antibody response (following injected antigen) and thus may be of value in subjects who have anaphylaxis (eg insect envenomation, and food and drug sensitivities).
  • probiotic bacteria can downregulate IgE production following antigen administration or exposure to antigen - thus continuous oral ingestion of appropriate doses of live bacteria selected by this method may be of value in the ongoing management of allergic disease.
  • administration of live probiotic bacteria is particularly effective
  • co-administration of probiotic bacteria with the antigen/allergen, or administration of probiotic bacteria shortly after the antigen/allergen challenge is particularly effective
  • the probiotic bacteria can be formulated into various compositions and preferably the compositions are pharmaceutical compositions in the form of capsules, tablets, powders and the like.
  • Such formulations can be prepared by known means, using pharmaceutically acceptable carriers, excipients, solvents or adjuvants. Such procedures and ingredients are well know and amply described in standard texts and manuals, for example "Remington: The Science and Practice of Pharmacy", 1995, Mack Publishing Co. Easton, PA 18042, USA, which is incorporated herein by reference.
  • the probiotic bacteria may also be formulated into food products by the usual well known means.
  • Bacteria ⁇ Lactobacillus acidophilus or Lactobacillus casei) were grown in MRS agar petri dishes (3.8% w/v, Oxoid, Basingstoke, UK). Plates were incubated in 5% CO 2 and air in a humid atmosphere at 37°C for 48 hours.
  • PBS phosphate buffered saline
  • mice Thirty female C57/B16 SPF mice (Animal Resource Centre, Perth, WA, Australia) were fed with 4 or 8 oral doses of 0.6-1.0 x 10 10 L acidophilus or L casei in 0.2 mL PBS or PBS alone given two days apart.
  • mice were injected intraperitoneally with 7 ⁇ g of egg albumin (ovalbumin. OVA, Sigma-Aldrich, St Loius, Missouri, USA) and 4 mg aluminium hydroxide (Amphojel, Whitehall Laboratories, Sydney, Australia) in 0.2 mL PBS or with PBS alone.
  • egg albumin ovalbumin. OVA, Sigma-Aldrich, St Loius, Missouri, USA
  • aluminium hydroxide aluminium hydroxide
  • mice Immunised and control mice were then placed on a feeding regime consisting of 8 oral doses of 0.6-1.0 x 10'° bacteria in PBS or PBS alone given two days apart. Mice were bled by the saphenous vein 2 days after the last dose and the serum collected for IgE antibody determination using an ELISA assay.
  • Example 2 Suppression of IgE response to OVA by L acidophilus after allergen sensitisation
  • mice were fed 10 10 L acidophilus before or 24 hrs after sensitisation with 8 ⁇ g ovalbumin (OVA) in alum per mouse.
  • Control mice were sham fed with normal saline.
  • a total of 10 feeds was administered before they were assessed for levels of OVA-specific IgE antibody and total IgE in serum.
  • L acidophilus was more effective if administered (or co-administered) at the time of exposure to OVA than when administered prior to allergen exposure, as shown by the suppression of OVA-specific IgE antibody and total IgE responses (Figure 2 ).
  • Data are mean + SEM from 5-10 mice. *, p ⁇ 0.05 compared with control values from saline-fed sensitised mice.
  • Example 3 Suppression of IgE response to OVA by L. acidophilus is dose- dependent Mice were fed orally with 10 8 . 10 9 or 10 10 L acidophilus before they were sensitised 24 hrs later with OVA in alum. Control mice were sham fed PBS. Each dose was administered 10 times every 2 days for 21 days. One week following the final dose, serum IgE and OVA-specific IgE antibody were measured. A dose-dependent suppression of IgE and OVA-specific IgE antibody was noted with a statistically significant effect with 10 l ⁇ bacteria ( Figure 3). Data are mean + SEM from 10 mice. *, p ⁇ 0.05 compared with control values from saline-fed sensitised mice.
  • mice were fed live or formalin-killed 10 10 L acidophilus and then sensitised with OVA as per standard protocol described in Example 3.
  • Figure 4 shows that live bacteria were more effective in suppressing IgE response than killed bacteria. Data are mean + SEM from 5 mice. *, p ⁇ 0.05 compared with values from saline-fed sensitised mice.
  • Example 5 Suppression of IgE response to OVA by L acidophilus correlates with cytokine and IgG antibody subclass response
  • mice fed 10'° L acidophilus produced higher amounts of IFN- ⁇ and lower amounts of IL-4 in the spleen, a finding consistent with the suppression of IgE response.
  • the contrasting cytokine patterns correlated with the production of salivary IgG subclass antibodies which showed an upregulation of IgG2a antibody and a downregulation of IgGl , respectively ( Figure 5 ).
  • Data are mean + SEM from 10 mice. *, p ⁇ 0.05; **, p ⁇ 0.01 compared with values from saline-fed sensitised mice.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des méthodes de réduction des taux d'IgE et des méthodes de traitement de l'allergie, reposant sur l'administration d'une dose efficace sur le plan thérapeutique de bactéries probiotiques vivantes, ou d'une composition contenant des bactéries probiotiques. En outre, cette invention concerne des méthodes d'identification des bactéries probiotiques utiles et des compositions contenant ces bactéries probiotiques.
PCT/AU2000/001414 1999-11-19 2000-11-20 Compositions et methodes pour le traitement des troubles allergiques WO2001037865A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
BR0015698-1A BR0015698A (pt) 1999-11-19 2000-11-20 Composições e métodos para tratamento de doenças alérgicas
EP00975685A EP1229930A4 (fr) 1999-11-19 2000-11-20 Compositions et methodes pour le traitement des troubles allergiques
HK03100999.8A HK1049115A1 (zh) 1999-11-19 2000-11-20 治療過敏性失調的成分和方法
CA002391499A CA2391499A1 (fr) 1999-11-19 2000-11-20 Compositions et methodes pour le traitement des troubles allergiques
AU13734/01A AU782689B2 (en) 1999-11-19 2000-11-20 Compositions and methods for treatment of allergic disorders
JP2001539479A JP2003514869A (ja) 1999-11-19 2000-11-20 アレルギー性疾患の処置のための組成物および方法
KR1020027006409A KR20020084066A (ko) 1999-11-19 2000-11-20 알러지성 질환의 치료 방법 및 그를 위한 조성물

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ4158 1999-11-19
AUPQ4158A AUPQ415899A0 (en) 1999-11-19 1999-11-19 Compositions for and methods of treatment of allergic diseases

Publications (1)

Publication Number Publication Date
WO2001037865A1 true WO2001037865A1 (fr) 2001-05-31

Family

ID=3818302

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2000/001414 WO2001037865A1 (fr) 1999-11-19 2000-11-20 Compositions et methodes pour le traitement des troubles allergiques

Country Status (9)

Country Link
EP (1) EP1229930A4 (fr)
JP (1) JP2003514869A (fr)
KR (1) KR20020084066A (fr)
CN (1) CN1391480A (fr)
AU (1) AUPQ415899A0 (fr)
BR (1) BR0015698A (fr)
CA (1) CA2391499A1 (fr)
HK (1) HK1049115A1 (fr)
WO (1) WO2001037865A1 (fr)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001097822A1 (fr) 2000-06-20 2001-12-27 Oy Aboatech Ab Probiotiques pour la prevention primaire de maladies atopiques
WO2003010299A1 (fr) * 2001-07-26 2003-02-06 Alimentary Health Limited Souches de lactobacillus casei probiotiques
WO2004002501A1 (fr) * 2002-06-26 2004-01-08 Calpis Co., Ltd. Agent anti-allergique, son utilisation pour reduire les allergies et procede de reduction d'allergies
WO2004096246A1 (fr) * 2003-03-13 2004-11-11 Kirin Beer Kabushiki Kaisha Composition antiallergique
JP2005068092A (ja) * 2003-08-26 2005-03-17 Ala:Kk 免疫促進用組成物
WO2005058335A1 (fr) * 2003-12-17 2005-06-30 N.V. Nutricia Bacteries de production d'acide lactique et fonction pulmonaire
US7125708B2 (en) 2001-10-12 2006-10-24 University Of Reading, School Of Food Biosciences Composition comprising a Lactobacillus pentosus strain and uses thereof
US7195906B2 (en) 1999-01-15 2007-03-27 Enterprise Ireland (Trading As Bioresearch Ireland) Bifidobacterium in the treatment of inflammatory disease
EP1994936A1 (fr) 2004-06-03 2008-11-26 Biogaia Ab Lactobacilli pour la prévention de la mammite et pour réduire le risque d'allergie chez un enfant allaité
EP2065048A1 (fr) * 2007-11-30 2009-06-03 Institut Pasteur Utilisation d'une souche de L. casei pour la préparation d'une composition pour l'inhibition de l'activation de mastocytes
EP1941892A3 (fr) * 2007-01-05 2009-08-19 Promd Biotech Co., Ltd. Agent antiallergénigue contenant une bactérie d' acide lactique
CN101328468B (zh) * 2007-06-21 2012-05-23 东宇生物科技股份有限公司 抗过敏的乳酸菌
CN102657260B (zh) * 2007-06-21 2013-08-21 东宇生物科技股份有限公司 抗过敏的乳酸菌
EP2244734B1 (fr) 2008-02-01 2016-05-04 Murdoch Childrens Research Institute Procédé d'induction de tolérance à un allergène
US20220347236A1 (en) * 2018-01-12 2022-11-03 Gl INNOVATION, INC. Composition comprising probiotics and polypeptide having binding affinity for ige and use thereof
WO2024081219A1 (fr) 2022-10-14 2024-04-18 Csp Technologies, Inc. Récipient et procédé de stockage et de stabilisation de produits sensibles à l'humidité

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4591810B2 (ja) * 2003-09-19 2010-12-01 日之出産業株式会社 花粉症アレルギー性鼻炎抑制用点鼻組成物
ES2500046T3 (es) 2010-08-10 2014-09-29 R.P. Scherer Technologies, Llc Proceso para la fabricación de una cápsula estable de gel blando que contiene bacterias probióticas microencapsuladas
KR101311989B1 (ko) * 2010-11-17 2013-09-26 주식회사한국야쿠르트 면역 조절 및 강화 효능을 갖는 락토바실러스 카제이 에이치와이7211를 유효성분으로 함유하는 제품
CN111296842B (zh) * 2020-02-14 2021-01-05 赵一鸣 一种具有抗敏作用的益生菌组合物
CN112375722B (zh) * 2021-01-18 2021-04-13 山东中科嘉亿生物工程有限公司 一种改善过敏的干酪乳杆菌lc-12及其产品、应用
CN117085046A (zh) * 2023-10-20 2023-11-21 潍坊君薇生物科技有限责任公司 嗜酸乳杆菌ls001后生元及其应用
CN117887643B (zh) * 2024-03-14 2024-06-14 微康益生菌(苏州)股份有限公司 一种抗过敏的益生菌剂及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH092959A (ja) * 1995-06-16 1997-01-07 Yakult Honsha Co Ltd ＩｇＥ抗体産生抑制剤および抗アレルギー剤
EP0904784A1 (fr) * 1997-09-22 1999-03-31 N.V. Nutricia Préparation nutritionnelle probiotique
JPH11199495A (ja) * 1998-01-10 1999-07-27 Nichinichi Seiyaku Kk 腸溶性カプセルを用いた抗アレルギー剤
WO1999042568A1 (fr) * 1998-02-20 1999-08-26 Mendes S.R.L. Utilisation d'une bacterie dotee de l'arginine deiminase pouvant provoquer l'apoptose et/ou reduire une reaction inflammatoire, et compositions pharmaceutiques ou dietetiques contenant ladite bacterie
AU710126B2 (en) * 1995-06-14 1999-09-16 Valio Oy Methods of preventing or treating allergies
JP2000004830A (ja) * 1998-06-24 2000-01-11 Asama Kasei Kk 免疫調節活性分解物およびその製造方法並びにそれを用いた食品

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5946488B2 (ja) 1978-08-07 1984-11-13 極東脂肪酸株式会社 アレルギ−反応抑制剤
JPS5946491B2 (ja) 1979-03-14 1984-11-13 極東脂肪酸株式会社 喘息治療剤
JPH07265064A (ja) 1993-11-23 1995-10-17 Taketoshi Yamada 腸内細菌叢改善組成物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU710126B2 (en) * 1995-06-14 1999-09-16 Valio Oy Methods of preventing or treating allergies
JPH092959A (ja) * 1995-06-16 1997-01-07 Yakult Honsha Co Ltd ＩｇＥ抗体産生抑制剤および抗アレルギー剤
EP0904784A1 (fr) * 1997-09-22 1999-03-31 N.V. Nutricia Préparation nutritionnelle probiotique
JPH11199495A (ja) * 1998-01-10 1999-07-27 Nichinichi Seiyaku Kk 腸溶性カプセルを用いた抗アレルギー剤
WO1999042568A1 (fr) * 1998-02-20 1999-08-26 Mendes S.R.L. Utilisation d'une bacterie dotee de l'arginine deiminase pouvant provoquer l'apoptose et/ou reduire une reaction inflammatoire, et compositions pharmaceutiques ou dietetiques contenant ladite bacterie
JP2000004830A (ja) * 1998-06-24 2000-01-11 Asama Kasei Kk 免疫調節活性分解物およびその製造方法並びにそれを用いた食品

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DUGAS B. ET AL.: "Immunity and probiotics", TRENDS IMMUNOLOGY TODAY, vol. 20, no. 9, September 1999 (1999-09-01), pages 387 - 390, XP008007353 *
HEYMAN M.: "Effect of lactic acid bacteria on diarrheal diseases", J. OF THE AMERICAN COLLEGE OF NUTRITION, vol. 19, no. 2, 2000, pages 137S - 146S, XP008007354 *
MATSUZAKI T. ET AL.: "The effect of oral feeding of lactobacillus casei strain shirota on immunoglobulin E production in mice", J. DAIRY SCIENCE, vol. 81, 1998, pages 48 - 53, XP001074168 *
PATENT ABSTRACTS OF JAPAN *
See also references of EP1229930A1 *
SHIDA K. ET AL.: "Lactobacillus casei inhibits antigen-induced IgE secretion through regulation of cytokine production in murine splenocyte cultures", INTERNATIONAL ARCHIVES OF ALLERGY & IMMUNOLOGY, vol. 115, 1999, pages 278 - 287, XP008007352 *
YASUI H. ET AL.: "Immunomodulatory functio of lactic acid bacteria", ANTONIE VAN LEEUWENHOEK, vol. 76, no. 1-4, 1999, pages 383 - 389, XP000979552 *

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7195906B2 (en) 1999-01-15 2007-03-27 Enterprise Ireland (Trading As Bioresearch Ireland) Bifidobacterium in the treatment of inflammatory disease
EP2201955A1 (fr) * 2000-06-20 2010-06-30 Nestec S.A. Probiotiques pour la prévention principale des maladies atopiques
WO2001097822A1 (fr) 2000-06-20 2001-12-27 Oy Aboatech Ab Probiotiques pour la prevention primaire de maladies atopiques
US7112322B2 (en) 2000-06-20 2006-09-26 Erika Isolauri Probiotics in primary prevention of atopic diseases
US7988960B2 (en) 2000-06-20 2011-08-02 Nestec S.A. Probiotics in primary prevention of atopic diseases
EP2206507A1 (fr) * 2000-06-20 2010-07-14 Nestec S.A. Probiotiques pour la prévention principale des maladies atopiques
WO2003010299A1 (fr) * 2001-07-26 2003-02-06 Alimentary Health Limited Souches de lactobacillus casei probiotiques
US7125708B2 (en) 2001-10-12 2006-10-24 University Of Reading, School Of Food Biosciences Composition comprising a Lactobacillus pentosus strain and uses thereof
WO2004002501A1 (fr) * 2002-06-26 2004-01-08 Calpis Co., Ltd. Agent anti-allergique, son utilisation pour reduire les allergies et procede de reduction d'allergies
CN100567489C (zh) * 2002-06-26 2009-12-09 卡尔皮斯株式会社 抗变态反应剂及其制药用途
US8003092B2 (en) 2002-06-26 2011-08-23 Calpis Co., Ltd. Antiallergic agent, utilization thereof for reducing allergy and method of reducing allergy
AU2003246204B2 (en) * 2002-06-26 2007-07-12 Calpis Co., Ltd Antiallergic agent, utilization thereof for reducing allergy and method of reducing allergy
CN1767839B (zh) * 2003-03-13 2012-08-22 麒麟控股株式会社 抗过敏的组合物
KR100908254B1 (ko) * 2003-03-13 2009-07-20 기린 홀딩스 가부시키가이샤 항알레르기용 조성물
AU2004233658B2 (en) * 2003-03-13 2009-10-29 Kirin Holdings Kabushiki Kaisha Antiallergic composition
WO2004096246A1 (fr) * 2003-03-13 2004-11-11 Kirin Beer Kabushiki Kaisha Composition antiallergique
JP2005068092A (ja) * 2003-08-26 2005-03-17 Ala:Kk 免疫促進用組成物
WO2005058335A1 (fr) * 2003-12-17 2005-06-30 N.V. Nutricia Bacteries de production d'acide lactique et fonction pulmonaire
EP3061458A1 (fr) 2004-06-03 2016-08-31 Biogaia Ab Procédé pour améliorer l'allaitement afin de réduire le risque d'allergie
EP1994936A1 (fr) 2004-06-03 2008-11-26 Biogaia Ab Lactobacilli pour la prévention de la mammite et pour réduire le risque d'allergie chez un enfant allaité
EP1941892A3 (fr) * 2007-01-05 2009-08-19 Promd Biotech Co., Ltd. Agent antiallergénigue contenant une bactérie d' acide lactique
CN101328468B (zh) * 2007-06-21 2012-05-23 东宇生物科技股份有限公司 抗过敏的乳酸菌
CN102657260B (zh) * 2007-06-21 2013-08-21 东宇生物科技股份有限公司 抗过敏的乳酸菌
WO2009068997A1 (fr) * 2007-11-30 2009-06-04 Institut Pasteur Utilisation d'une souche de l. casei pour la préparation d'une composition destinée à inhiber l'activation des mastocytes
EP2065048A1 (fr) * 2007-11-30 2009-06-03 Institut Pasteur Utilisation d'une souche de L. casei pour la préparation d'une composition pour l'inhibition de l'activation de mastocytes
EP2244734B1 (fr) 2008-02-01 2016-05-04 Murdoch Childrens Research Institute Procédé d'induction de tolérance à un allergène
US10071157B2 (en) 2008-02-01 2018-09-11 Murdoch Childrens Research Institute Method of inducing tolerance to an allergen
US20220347236A1 (en) * 2018-01-12 2022-11-03 Gl INNOVATION, INC. Composition comprising probiotics and polypeptide having binding affinity for ige and use thereof
US12128076B2 (en) * 2018-01-12 2024-10-29 Gi Innovation, Inc. Composition comprising probiotics and polypeptide having binding affinity for IgE and use thereof
WO2024081219A1 (fr) 2022-10-14 2024-04-18 Csp Technologies, Inc. Récipient et procédé de stockage et de stabilisation de produits sensibles à l'humidité

Also Published As

Publication number Publication date
EP1229930A1 (fr) 2002-08-14
CN1391480A (zh) 2003-01-15
JP2003514869A (ja) 2003-04-22
AUPQ415899A0 (en) 1999-12-16
CA2391499A1 (fr) 2001-05-31
BR0015698A (pt) 2002-07-23
EP1229930A4 (fr) 2004-09-22
HK1049115A1 (zh) 2003-05-02
KR20020084066A (ko) 2002-11-04

Similar Documents

Publication Publication Date Title
WO2001037865A1 (fr) Compositions et methodes pour le traitement des troubles allergiques
Jirillo et al. Anti-inflammatory and anti-allergic properties of donkey’s and goat’s milk
AU2009208390B2 (en) A method of inducing tolerance to an allergen
CN102168043B (zh) 可作为免疫调节剂的副干酪乳酸杆菌lt12
HK1217914A1 (zh) 稳定的油产品及其制备方法和提高乳酸杆菌菌株存活的方法
Velez et al. Probiotic fermented milk consumption modulates the allergic process induced by ovoalbumin in mice
US20100233162A1 (en) LOCAL ADMINISTRATION OF CHICKEN YOLK IMMUNE GLOBULINS (IgY) TO TREAT AND PREVENT FUNGAL INFECTIONS
JP2022537178A (ja) プレボテラ調製物ならびに慢性閉塞性肺疾患（ｃｏｐｄ）および他の肺状態の治療
JP2004512307A (ja) 心血管障害の診断および治療のための組成物および方法
FI120136B (fi) Mycobacterium vaccae immuunijärjestelmän Th2-aktiivisuuden hillitsemiseksi
AU782689B2 (en) Compositions and methods for treatment of allergic disorders
WO2011071370A1 (fr) Bactéries lactiques probiotiques
Singh et al. Probiotics in allergy prevention
JP2005126365A (ja) 減感作療法用剤
WO2021162563A1 (fr) Lipopolysaccharides pour le traitement d'allergies alimentaires
Chudzik-Kozłowska et al. BALB/C mice as a model for immunogenicity testing of food proteins on the example of egg ovalbumin
Frøkiær 26 Probiotics and the
KR101275227B1 (ko) 중증근무력증 예방, 개선 또는 치료용 조성물
Viljanen Effects of probiotic bacteria on symptoms and on immunologic responses in infants with atopic dermatitis
Crittenden et al. The MAM Study: a clinical study of milk allergy mechanisms in adults
MXPA99005553A (en) Mycobacterium vaccae
Meijerink et al. A comparative study of the immunomodulatory properties of potential probiotics in vitro and in vivo using a mouse model of peanut allergy
HK1166670A (en) A stabilized oil product and its method of preparation and method of increasing survival of a lactic acid bacteria strain
HK1100508B (en) A use of a lactic acid bacterial in preparation for pharmaceuticals for improving breast milk of feeding a baby

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2391499

Country of ref document: CA

Ref document number: IN/PCT/2002/00610/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 00815855X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 1020027006409

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2001 539479

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000975685

Country of ref document: EP

Ref document number: 13734/01

Country of ref document: AU

Ref document number: 519280

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 2000975685

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020027006409

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 13734/01

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 2000975685

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)